ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: In PTCL with PD-L1 expression>50%, the ORR (53.3%) and median PFS (6.2 months) were higher, especially in ENKTL, ALK-ALCL, ALK+ALCL, Geptanolimab has a better curative effect (148).